Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cysteinase is a **novel engineered enzyme** designed to deplete extracellular cysteine and cystine, thereby starving rapidly growing cells, such as cancer cells, of these amino acids necessary for their survival and proliferation. As opposed to endogenous enzymes, cysteinase is **not a naturally occurring enzyme** but was **bioengineered** to catalyze the breakdown of cysteine/cystine with high efficiency. The principal mechanism of action is the **depletion of extracellular cysteine/cystine**, leading to suppression of glutathione synthesis and increased oxidative stress in target tissues, notably tumor cells. This approach is being investigated for its potential utility in **oncology**, particularly for the treatment of solid tumors such as pancreatic cancer, exploiting cancer cells’ dependence on external cysteine. The development of cysteinase is currently experimental, with most information derived from preclinical studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cysteinase.